| Ytd | -14.30% | |
| 1y | 4.98% |
| Open | 3.22 | Prev Close | 3.21 | Low | 3.18 | High | 3.27 | Mkt Cap | 339.18M |
| Vol | 264.22K | Avg Vol | 2.08M | EPS | -2.12 | P/E | N/A | Forward P/E | -2.57 |
| Beta | 0.71 | Short Ratio | 5.19 | Inst. Own | 106.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.72 | 200-d Avg | 3.97 | 1yr Est | 20.41 |
LRMR News
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) wit
NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowe
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp i
Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigat
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes
BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR
BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR
JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Ov
Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lo
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the ana
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and ra
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the a
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and ra
Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology compan
Larimar Therapeutics Inc (NASDAQ:LRMR) shares are soaring on Wednesday after multiple analysts reite
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and r
Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and m
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.61) per share which missed the a
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The comp
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce
